Therapeutic Effect of Whole Brain Radiotherapy on Advanced NSCLC Between EGFR TKI-naïve and TKI-resistant

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2020 Jan 2

PMID 31892337

Citations 5

Authors

Lihao Zhao

Xiaona Cai

Didi Chen

XuXue Ye

Mengdan Gao

Lihuai Lu

Huafang Su

Meng Su

Meng Hou

Congying Xie

Affiliations

Soon will be listed here.

Abstract

Background: The development of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has dramatically improved the prognosis of patients with EGFR-mutant non-small-cell lung cancer (NSCLC). The purpose of this study is to investigate the clinical outcome with or without EGFR-TKI resistance before WBRT and the sequence between EGFT-TKIs and whole brain radiotherapy (WBRT) of EGFR-mutant NSCLC patients who developed multiple brain metastases (BMs).

Patients And Methods: Three hundred forty-four EGFR-mutant NSCLC patients with multiple BMs were reviewed. Enrolled patients were divided into TKI-naïve group and TKI-resistant group. The intracranial progression-free survival (PFS) and overall survival (OS) were analyzed via the Kaplan-Meier method.

Results: For patients with multiple BMs treated by WBRT, the median intracranial PFS and OS were longer in the TKI-naïve group than those in the TKI-resistant group, but there were no statistically significant between two groups (Intracranial PFS: 7.7 vs. 5.4 months, p = 0.052; OS: 11.2 vs. 9.2 months, p = 0.106). For patients with Lung-molGPA 0-2, no significant differences in median intracranial PFS (6.2 vs. 5.2 months, p = 0.123) and OS (7.8 vs. 6.7 months, p = 0.514) between TKI-naïve and TKI-resistant groups. For patients with Lung-molGPA 2.5-4, intracranial PFS: 12.8 vs. 10.1 months; OS: 23.3 vs. 15.3 months.

Conclusions: Our study found that there were no difference in intracranial PFS and OS in all patients between the two groups of TKI-naïve and TKI-resistant. But for patients in subgroup of Lung-molGPA 2.5-4, there were a better intracranial PFS and OS in TKI-naïve group.

Citing Articles

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.

Khasraw M, Yalamanchili P, Santhanagopal A, Wu C, Salas M, Meng J Adv Ther. 2024; 41(5):1815-1842.

PMID: 38509433 PMC: 11052832. DOI: 10.1007/s12325-024-02799-9.

Anlotinib combined with whole-brain radiotherapy in non-small cell lung cancer with multiple brain metastases that progressed or developed after at least one lines of prior treatment.

Kong C, Yu S, Qian P, Song X, Wen J, Jiang M Front Oncol. 2023; 13:1169333.

PMID: 37771446 PMC: 10523148. DOI: 10.3389/fonc.2023.1169333.

EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?.

Liu B, Liu H, Ma Y, Ding Q, Zhang M, Liu X Cancer Med. 2021; 10(18):6167-6188.

PMID: 34374490 PMC: 8446557. DOI: 10.1002/cam4.4192.

Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.

Zhong Q, Liu Z Cancer Manag Res. 2021; 13:4115-4128.

PMID: 34045898 PMC: 8149213. DOI: 10.2147/CMAR.S304838.

Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer.

Jablonska P, Bosch-Barrera J, Serrano D, Valiente M, Calvo A, Aristu J Cancers (Basel). 2021; 13(9).

PMID: 33946751 PMC: 8124815. DOI: 10.3390/cancers13092141.

References

Sperduto P, Yang T, Beal K, Pan H, Brown P, Bangdiwala A . Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2016; 3(6):827-831. PMC: 5824323. DOI: 10.1001/jamaoncol.2016.3834. View

Steuer C, Ramalingam S . Targeting EGFR in lung cancer: Lessons learned and future perspectives. Mol Aspects Med. 2015; 45:67-73. PMC: 5024712. DOI: 10.1016/j.mam.2015.05.004. View

Venur V, Ahluwalia M . Prognostic scores for brain metastasis patients: use in clinical practice and trial design. Chin Clin Oncol. 2015; 4(2):18. DOI: 10.3978/j.issn.2304-3865.2015.06.01. View

La Fleur L, Johansson A, Roberg K . A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment. PLoS One. 2012; 7(9):e44071. PMC: 3458050. DOI: 10.1371/journal.pone.0044071. View

Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K . In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000; 6(2):701-8. View

Bilous M, Serdjebi C, Boyer A, Tomasini P, Pouypoudat C, Barbolosi D . Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer. Sci Rep. 2019; 9(1):13018. PMC: 6736889. DOI: 10.1038/s41598-019-49407-3. View

Lee Y, Choi H, Kim S, Chang J, Moon J, Park I . Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer. 2010; 116(5):1336-43. DOI: 10.1002/cncr.24877. View

Yang J, Zhou C, Huang Y, Feng J, Lu S, Song Y . Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet Respir Med. 2017; 5(9):707-716. DOI: 10.1016/S2213-2600(17)30262-X. View

Wang C, Lu X, Lyu Z, Bi N, Wang L . Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis. Lung Cancer. 2018; 122:94-99. DOI: 10.1016/j.lungcan.2018.05.014. View

10.

Lukas R, Wainwright D, Laterra J . Updates from the Neuro-Oncology Section of the 2015 American Neurological Association Annual Meeting. Future Oncol. 2015; 12(2):143-7. PMC: 4743646. DOI: 10.2217/fon.15.299. View

11.

Javvadi P, Makino H, Das A, Lin Y, Chen D, Chen B . Threonine 2609 phosphorylation of the DNA-dependent protein kinase is a critical prerequisite for epidermal growth factor receptor-mediated radiation resistance. Mol Cancer Res. 2012; 10(10):1359-68. PMC: 3475795. DOI: 10.1158/1541-7786.MCR-12-0482-T. View

12.

Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins S . Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005; 65(8):3328-35. DOI: 10.1158/0008-5472.CAN-04-3547. View

13.

Lee H, Chung T, Ting L, Tsai J, Chen S, Chiou J . EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol. 2012; 7:181. PMC: 3549835. DOI: 10.1186/1748-717X-7-181. View

14.

Knisely J, Berkey B, Chakravarti A, Yung A, Curran Jr W, Robins H . A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008; 71(1):79-86. DOI: 10.1016/j.ijrobp.2007.09.016. View

15.

Kosaka T, Yamaki E, Mogi A, Kuwano H . Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol. 2011; 2011:165214. PMC: 3114474. DOI: 10.1155/2011/165214. View

16.

Magnuson W, Yeung J, Guillod P, Gettinger S, Yu J, Chiang V . Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. Int J Radiat Oncol Biol Phys. 2016; 95(2):673-9. DOI: 10.1016/j.ijrobp.2016.01.037. View

17.

Huang S, Li J, Armstrong E, Harari P . Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 2002; 62(15):4300-6. View

18.

Porta R, Sanchez-Torres J, Paz-Ares L, Massuti B, Reguart N, Mayo C . Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2010; 37(3):624-31. DOI: 10.1183/09031936.00195609. View

19.

Zeng Y, Liao H, Qin T, Zhang L, Wei W, Liang J . Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget. 2015; 6(10):8366-76. PMC: 4480758. DOI: 10.18632/oncotarget.3187. View

20.

Chen K, Yu X, Zhang F, Xu Y, Zhang P, Huang Z . Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases. Lung Cancer. 2018; 125:8-13. DOI: 10.1016/j.lungcan.2018.08.023. View